Pseudophakic cystoid macular edema: Ketorolac alone vs. ketorolac plus prednisolone

Canadian Journal of Ophthalmology

Volumn 39, Issue 3, 2004, Pages 245-250

  Singal, Neera ^a   Hopkins, Jill ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

NSAIDs; Pseudophakic cystoid macular edema; Steroids; Visually significant

Indexed keywords

KETOROLAC TROMETAMOL; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISOLONE; STEROID;

ACUTE DISEASE; AGED; ARTICLE; CATARACT; CATARACT EXTRACTION; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC RETINOPATHY; DOUBLE BLIND PROCEDURE; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; MALE; PHACOEMULSIFICATION; PROSPECTIVE STUDY; PSEUDOPHAKIA; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA CYSTOID EDEMA; RETINA MACULA HOLE; TREATMENT OUTCOME;

EID: 2442525919     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.1016/S0008-4182(04)80121-2     Document Type: Article

References (13)

1. Rocha G, Deschênes J. Pathophysiology and treatment of cystoid macular edema. Can J Ophthalmol 1996;31(6):282-8.
2. Burnett J, Tessler H, Isenberg S, Tso MOM. Double-masked trial of fenoprofen sodium; treatment of chronic aphakic cystoid macular edema. Ophthalmic Surg 1983;14:150-2.
3. Heier JS, Topping MD. Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Am J Ophthalmol 2000;107:2034-8.
4. Flach AJ, Dolan BJ, Irvine AR. Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema. Am J Ophthalmol 1987;103:479-86.
5. Flach AJ, Jampol LM, Weinberg D, Kraff MC, Yannuzzi LA, Campo RV, et al. Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. Am J Ophthalmol 1991;112:514-9.
6. David DS, Berkowitz JS. Ocular effects of topical and systemic corticosteroids. Lancet 1969;2:149-51.
7. Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology 1991;98(5 Suppl):741-56.
8. Miyake K, Sakamura S. Long-term follow-up study on prevention of aphakic cystoid macular oedema by topical indomethacin. Br J Ophthalmol 1980;64:324-8.
9. Hintze JL. PASS 2000: power analysis and sample size for Windows. Kaysville (UT): NCSS; 2000.
10. Irvine SR. A newly defined vitreous syndrome following cataract surgery. Am J Ophthalmol 1953;36:599-619.
11. Gass JDM, Norton EWD. Fluorescein studies of patients with macular edema and papilledema following cataract extraction. Trans Am Ophthalmol Soc 1966;64:232-9.
12. Norton AL, Brown WJ, Carlson M, Pilger IS, Riffenburgh RS. Pathogenesis of aphakic macular edema. Am J Ophthalmol 1975;80:96-101.
13. Insel PA. Analgesic-antipyretics and anti-inflammatory agents: drugs employed in the treatment of rheumatoid arthritis and gout. In: Gilman AG, Rall TW, Nies AS, Taylor P, editors. Goodman and Gilman's pharmacologic basis of therapeutics. 8th ed. New York: Pergamon Press; 1990. p. 669-70.